Skip to content
Image of Ayse

Ayse Ulgen

Senior Lecturer



Senior Lecturer in Statistics, Department of Mathematics, School of Science and Technology

Career overview

Biostatistics Ph.D. and Master of Global Management graduate. Several years of research and research management, consulting, academic, customer relations and marketing experience creating partnerships in clinical, biotechnology, biostatistics, genetic epidemiology and personalized medicine using statistical and big data analytical approaches with leading universities and biotech companies. Established and maintained peer to peer relationships with leading Key Opinion Leaders, physicians, scientists at major academic institutions and companies. Expertise includes developing and applying novel biostatistical and epidemiological methodologies to oncology, infectious diseases, epilepsy, neuropsychiatric disorders and asthma. Strong networking, communication and negotiation skills. Highly adaptable and resourceful with extensive cross-cultural international experience having worked in six different countries. Outstanding analytical and research skills, combined with advanced knowledge of statistics and big data. Project management skills, including supervision and peer review processes with subject matter experts. Outstanding leadership skills, with experience leading cross-cultural teams and projects, and collaborating across sectors and departments. Excellent communication and public speaking skills with 25+ published articles and 20+ professional presentations. Creative and artistic flair with a passion to add value to any organization.

Research areas

  • Medical Statistics
  • Biostatistics
  • Genetic  Epidemiology
  • Computational  Statistics
  • Machine Learning

External activity

Current / Future Research collaborators:

  • Dr Wentian Li (Robert Boas Center  for Genomics and Human Genetics, Feinstein  Institute of Medical Research)
  • Dr Ioannis Vlachos  (Harvard University Medical School)
  • Dr Sirin Cetin (Amasya University)
  • Dr Janet Meiling  Roveda (University of Arizona)
  • Dr Steven Brown, Dr Daniel King (Nottingham Trent University)


  1. A Ulgen, S Cetin, M Cetin H Sivgin, W Li. A Composite Ranking of Risk Factors for COVID-19 Time-To-Event Data from a Turkish Cohort. Computational Biology and Chemistry. 2022, 98 (2022) 107681.
  2. M Cetin, S Cetin, A Ulgen, W Li. Blood-Type-A Is A COVID-19 Infection and Hospitalization Risk In a Turkish Cohort. Transfusion Clinique et Biologique, ISSN 1246-7820, 2022.
  3. E Berksel, A Ulgen. Magnitude of antibody response and risk factors for reduced immunogenicity after two doses of an inactivated whole-virion COVID-19 vaccine (CoronaVac®). Cyprus Journal of Medical Sciences.2022, 7(4): 438-443.
  4. M Cetin, PO Balci, H Sivgin, S Cetin, A Ulgen, Wentian Li. Alpha Variant (B.1.1.7) of SARS-CoV-2 Increases Fatality-Rate for <70 years Old Patients and Hospitalization Risk Overall. Acta Microbiologica et Immunologica Hungarica. 2021,68(2021)3,153–61.
  5. A Ulgen, S Cetin, I Dede. ‘Survival Analysis in Colon Cancer Patients’. May 2021; J of Contemp Med 11(3):374-379.
  6. S Cetin, A Ulgen, PO Balci, H Sivgin, M Cetin, H Sivgin, W Li.  Survival Analyses of COVID-19 Patients in a Turkish Cohort: Comparison between Using Time to Death and Time to Release. Apr 2021; SciMedicine: Vol 3, Special Issue COVID-19:1-9.
  7. 7. S Cetin, A Ulgen, I Dede, W Li. ‘On Fair Comparison between Random Survival Forest and Cox Regression: An Example of Colorectal Cancer Study’. Mar 2021; SciMedicine: Vol 3(1):66-76. DOI: 10.28991/SciMedJ-2021-0301-9
  8. S Cetin, O Pasin, I Dede, A Ulgen. An application of a cox mixed cure model for breast cancer patients. 2021; Turkiye Klinikleri J of Biostat, 13(2):131-7. doi:10.5336/biostatic.2020-79287
  9. S Cetin, K Kose, E Karaaslan, A.Ulgen. Nonparametric Randomization-Based Analysis of Covariance Method in Repeated Clinical Categorical Data. 2021, Turkiye Klinikleri J Biostat: 13(1):50-6. doi: 10.5336/biostatic.2020-79326
  10. S Cetin, A Ulgen, H Sivgin, W Li. Approximate Reciprocal Relationship Between Two Cause-Specific Hazard Ratios in COVID-19 Data with Mutually Exclusive Events. Apr 2021, MedRxiv:1-20.
  11. A Ulgen, O Gurkut, W Li. Potential Predictive Factors for Breast Cancer Subtypes from a North Cyprus Cohort Analysis. Dec, 2020 Cyprus Journal of Medical Sciences. 5(4): 339-49.  doi: 10.5152/cjms.2020.2291
  12. S Cetin, A Ulgen, H Sivgin, W Li. ‘A Study On Factors Impacting Length of Hospital Stay of COVID-19 Inpatients’. May 2021; J of Contemporary Medicine 11(3): 396-404.
  13. H Acar, A Ulgen. ‘Comparison of Cost, Risks and Benefits of Robotic or Open Thyroidectomy on Thyroid Cancer’. Cyprus Journal of Medical Sciences.  Cyprus J Med Sci, 2021;6(1):1-6
  14. H Acar, A Ulgen.  Relationship between Thyroid Hormone Levels and Crime Type: A Controlled Study in Prisoners. International Journal of Endocrinology. vol. March 2020, Article ID 9172134, pp1-7.
  15. A Ulgen, C Amos. Quantitative Trait Loci on Chromosome 21 have Pleiotropic Effects on %FEV1 and Allergen Polysensitization: asthma related traits in the EGEA study. April 2020. Medrxiv: 1-36.
  16. CJ Morgan, MJ. Coleman, A Ulgen, L Boling, JO. Cole, FV. Johnson, J Lerbinger, JA Bodkin, PS. Holzman, D L. Levy. Thought Disorder in Schizophrenia and Bipolar Disorder Probands and Their Relatives. J. Schizophrenia Bulletin, March 1,2017.
  17. A Poduri, Y Wang, D Gordon, SB-Rodriguez, CB-Cummings, A Ulgen, V Chitsazzadeh, RS Hill, N Risch, WA Hauser, TA. Pedley, CA. Walsh, R Ottman. Novel Susceptibility Locus in a Family with GEFS+ Syndrome. Oct 2009, Neurology J, 20;73(16):1264-72
  18. H Aschard, E Bouzigon, A Ulgen, E Corda, MH Dizier, F Gormand, M Lathrop, F Kauffman, F Demenais. Sex-specific effect of IL9 polymorphisms on lung function and polysensitization. Sep 2009, Genes and Immunity Journal;10(6):559-65
  19. E Bouzigon, A Ulgen, MH Dizier, V Siroux, M Lathrop, F Kauffman, I Pin, F Demenais. Evidence for a pleiotropic QTL on chromosome 5q13 influencing both time to asthma onset and asthma score in French EGEA families. 2007, Hum Genet, Vol 121, 6: 711-719
  20. A Ulgen, W Li. Comparing Single-Nucleotide Polymorphism Marker-Based and Microsatellite Marker-Based Linkage Analyses. Dec 2005, BMC Genetics, 6(Suppl I):S13;p1-5. doi: 10.1186/1471-2156-6-S1-S13
  21. A Ulgen, YJ Yoo, D Gordon, SJ Finch, NR Mendell. Percentiles of the Null Distribution of 2 Maximum Lod Score Tests. 2004, Human Heredity, 57(1):39-48.
  22. A Ulgen, Z Han, W Li. Correlation between quantitative traits and correlation between corresponding LOD scores: detection of pleiotropic effects.2003, BMC Genetics, 4(Suppl 1): S60-66. DOI: 10.1186/1471-2156-4-S1-S60
  23. A Ulgen, S Cetin, PO Balci, H Sivgin, S Sivgin, M Cetin, W Li..  ‘COVID-19 Outpatients and Surviving Inpatients Exhibit Comparable Blood Test Results That Are Distinct From Non-Surviving Inpatients’. May 2021; J of Health Sci Med: 4(3):306-313.
  24. N Bekiroglu, A Ulgen. Application of Parametric Accelerated Failure Time (AFT) Model in Early Stage Breast Cancer Patients. July 2021; Pamukkale Medical J 14(3): 654-665.

Publications Accepted for Publication:

  1. 25.  W Li, S Cetin, A Ulgen, M Cetin, H Sivgin, Y Yang. ‘Approximate Reciprocal Relationship Between Two Cause-Specific Hazard Ratios in COVID-19 Data with Mutually Exclusive Events.’, Int J of Biostatistics, Walter de Gruyter.(Accepted).